{"success":true,"data":{"pressRelease":{"id":"105997","rtpr_id":"nGNX9mJs54","ticker":"REGN","exchange":"NASDAQ","all_tickers":["REGN"],"title":"REGN Class Action Notice: Regeneron Hit with Securities Fraud Lawsuit over Trial Misrepresentations – Investors Urged to Contact BFA Law by September 14 Deadline","author":"Globe Newswire","published_at":"2026-08-03T10:36:00.490Z","article_body":"NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Leading securities law\nfirm Bleichmar Fonti & Auld LLP\n(https://www.globenewswire.com/Tracker?data=7n2wJQVTBY2Y7qgNtPduorI_7RYl__OXbYLXefbQ9NDOE6K7Eu7yH5NVKqzG3Nky-eXwpbQjGV_2DEh-hHXqYl5G7VpuW8NKdfz5BkEKv5LbzWLyDty4rpzNvKTAUIW8GKnrsniWEorlkUHlAsdUvKeT-p3L-pfkw6ARJ61eOwk=)\nannounces that a class action lawsuit has been filed against Regeneron\nPharmaceuticals, Inc. (NASDAQ:REGN) and certain of the company’s senior\nexecutives for securities fraud after significant stock drops resulting from\npotential violations of the federal securities laws.\n\nIf you invested in Regeneron, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/regeneron-class-action-lawsuit.\n\nKey Details of the Regeneron ($REGN) Class Action:\n* Lead Plaintiff Deadline: September 14, 2026\n* Alleged Misconduct: Securities fraud alleging that Regeneron misled\ninvestors regarding the success of its Phase III Fianlimab-Libtayo clinical\ntrial\n* Stock Drop:  * April 29, 2026 – 6.2% Stock Drop\n* May 15, 2026 – 9.8% Stock Drop\n \n* Court: U.S. District Court for the Southern District of New York\n* Action: Contact BFA Law\n(https://www.bfalaw.com/cases/regeneron-class-action-lawsuit) to discuss your\nrights\nInvestors have until September 14, 2026, to ask the Court to be appointed to\nlead the case. The complaint asserts securities fraud claims under Sections\n10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors\nin Regeneron securities. The class action is pending in the U.S. District\nCourt for the Southern District of New York. It is captioned Cheathem v.\nRegeneron Pharm., Inc., et al., No. 26-cv-6026.\n\nWhy is Regeneron Being Sued for Securities Fraud?\n\nRegeneron is a pharmaceutical company that discovers, invents, develops,\nmanufactures, tests, and commercializes medicines to treat various disorders.\n\nDuring the relevant period, Regeneron was investigating Fianlimab, a human\nmonoclonal antibody targeting the LAG-3 immune checkpoint receptor on T-cells.\nSpecifically, Regeneron was testing Fianlimab in combination with Libtayo in a\nPhase III study to determine whether the drug combination could serve as a\nfirst-line treatment for advanced melanoma.\n\nRegeneron told investors that it had “a lot of hope and confidence” that\nthe Phase III trial “can generate a meaningful differentiation against\ncurrent standards of care.” Further, despite acknowledging that study\nresults had slowed, Regeneron told investors that this was likely because\n“there was a high level of response and those response[s] are very\ndurable” and that the combination drug was a “potential blockbuster.”\n\nIn truth, as alleged, the Phase III Fianlimab-Libtayo study did not achieve\nstatistically significant results.\n\nWhy did Regeneron’s Stock Drop?\n\nOn April 29, 2026, before market hours, Regeneron announced the Phase III\nFianlimab-Libtayo study “will now consider all patients enrolled in the\nstudy with a minimum follow-up of 6 months.” This expansion of the study\nparameters indicated the study did not have enough positive results to achieve\nstatistical significance. This news caused the price of Regeneron stock to\ndecline $45.41 per share, or 6.2%, from a closing price of $731.77 per share\non April 28, 2026, to $686.36 per share on April 29, 2026.\n\nThen, on May 15, 2026, after market hours, Regeneron published a press release\nstating that the Phase III Fianlimab-Libtayo “did not reach statistical\nsignificance for the primary endpoint” tested. This news caused the price of\nRegeneron stock to decline $68.57 per share, or 9.8%, from a closing price of\n$698.25 per share on May 15, 2026, to $629.68 per share on May 18, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/regeneron-class-action-lawsuit.\n\nWhat Can You Do?\n\nIf you invested in Regeneron, you may have legal options and are encouraged to\nsubmit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/regeneron-class-action-lawsuit\n\nOr contact:\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named “Elite Trial Lawyers” by the National Law Journal,\n“Litigation Stars” by Benchmark Litigation, among the top “500 Leading\nPlaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’\nBar” by Law360 and “SuperLawyers” by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff’s securities litigation law firm, with clients\nnoting: “[t]here is no better service provider in the practice area,”\n“[t]he interest of the client is always front and center,” and “[t]here\nisn’t a better firm in this space.” One testimonial described the firm as\n“nimble and entrepreneurial,” with a “relentless focus on adding value\nfor clients.”\n\nAmong its recent notable successes, BFA recovered over $900 million in value\nfrom Tesla, Inc.’s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/regeneron-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/44a256cf-d470-4d8a-af6b-dbb1b5bbb11e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9mJs54","title":"REGN Class Action Notice: Regeneron Hit with Securities Fraud Lawsuit over Trial Misrepresentations – Investors Urged to Contact BFA Law by September 14 Deadline","author":"Globe Newswire","ticker":"REGN","created":"2026-08-03T10:36:00.490Z","tickers":["REGN"],"exchange":"NASDAQ","article_body":"NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Leading securities law\nfirm Bleichmar Fonti & Auld LLP\n(https://www.globenewswire.com/Tracker?data=7n2wJQVTBY2Y7qgNtPduorI_7RYl__OXbYLXefbQ9NDOE6K7Eu7yH5NVKqzG3Nky-eXwpbQjGV_2DEh-hHXqYl5G7VpuW8NKdfz5BkEKv5LbzWLyDty4rpzNvKTAUIW8GKnrsniWEorlkUHlAsdUvKeT-p3L-pfkw6ARJ61eOwk=)\nannounces that a class action lawsuit has been filed against Regeneron\nPharmaceuticals, Inc. (NASDAQ:REGN) and certain of the company’s senior\nexecutives for securities fraud after significant stock drops resulting from\npotential violations of the federal securities laws.\n\nIf you invested in Regeneron, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/regeneron-class-action-lawsuit.\n\nKey Details of the Regeneron ($REGN) Class Action:\n* Lead Plaintiff Deadline: September 14, 2026\n* Alleged Misconduct: Securities fraud alleging that Regeneron misled\ninvestors regarding the success of its Phase III Fianlimab-Libtayo clinical\ntrial\n* Stock Drop:  * April 29, 2026 – 6.2% Stock Drop\n* May 15, 2026 – 9.8% Stock Drop\n \n* Court: U.S. District Court for the Southern District of New York\n* Action: Contact BFA Law\n(https://www.bfalaw.com/cases/regeneron-class-action-lawsuit) to discuss your\nrights\nInvestors have until September 14, 2026, to ask the Court to be appointed to\nlead the case. The complaint asserts securities fraud claims under Sections\n10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors\nin Regeneron securities. The class action is pending in the U.S. District\nCourt for the Southern District of New York. It is captioned Cheathem v.\nRegeneron Pharm., Inc., et al., No. 26-cv-6026.\n\nWhy is Regeneron Being Sued for Securities Fraud?\n\nRegeneron is a pharmaceutical company that discovers, invents, develops,\nmanufactures, tests, and commercializes medicines to treat various disorders.\n\nDuring the relevant period, Regeneron was investigating Fianlimab, a human\nmonoclonal antibody targeting the LAG-3 immune checkpoint receptor on T-cells.\nSpecifically, Regeneron was testing Fianlimab in combination with Libtayo in a\nPhase III study to determine whether the drug combination could serve as a\nfirst-line treatment for advanced melanoma.\n\nRegeneron told investors that it had “a lot of hope and confidence” that\nthe Phase III trial “can generate a meaningful differentiation against\ncurrent standards of care.” Further, despite acknowledging that study\nresults had slowed, Regeneron told investors that this was likely because\n“there was a high level of response and those response[s] are very\ndurable” and that the combination drug was a “potential blockbuster.”\n\nIn truth, as alleged, the Phase III Fianlimab-Libtayo study did not achieve\nstatistically significant results.\n\nWhy did Regeneron’s Stock Drop?\n\nOn April 29, 2026, before market hours, Regeneron announced the Phase III\nFianlimab-Libtayo study “will now consider all patients enrolled in the\nstudy with a minimum follow-up of 6 months.” This expansion of the study\nparameters indicated the study did not have enough positive results to achieve\nstatistical significance. This news caused the price of Regeneron stock to\ndecline $45.41 per share, or 6.2%, from a closing price of $731.77 per share\non April 28, 2026, to $686.36 per share on April 29, 2026.\n\nThen, on May 15, 2026, after market hours, Regeneron published a press release\nstating that the Phase III Fianlimab-Libtayo “did not reach statistical\nsignificance for the primary endpoint” tested. This news caused the price of\nRegeneron stock to decline $68.57 per share, or 9.8%, from a closing price of\n$698.25 per share on May 15, 2026, to $629.68 per share on May 18, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/regeneron-class-action-lawsuit.\n\nWhat Can You Do?\n\nIf you invested in Regeneron, you may have legal options and are encouraged to\nsubmit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/regeneron-class-action-lawsuit\n\nOr contact:\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named “Elite Trial Lawyers” by the National Law Journal,\n“Litigation Stars” by Benchmark Litigation, among the top “500 Leading\nPlaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’\nBar” by Law360 and “SuperLawyers” by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff’s securities litigation law firm, with clients\nnoting: “[t]here is no better service provider in the practice area,”\n“[t]he interest of the client is always front and center,” and “[t]here\nisn’t a better firm in this space.” One testimonial described the firm as\n“nimble and entrepreneurial,” with a “relentless focus on adding value\nfor clients.”\n\nAmong its recent notable successes, BFA recovered over $900 million in value\nfrom Tesla, Inc.’s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/regeneron-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/44a256cf-d470-4d8a-af6b-dbb1b5bbb11e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-03T10:36:00.573775711Z","server_sent_at_ms":1785753360573},"received_at":"2026-08-03T10:36:00.635Z","source_url":null},"analysis":{"id":"95008","press_release_id":"105997","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Bleichmar Fonti & Auld LLP issued a shareholder-solicitation notice regarding a class action lawsuit against Regeneron, alleging securities fraud tied to the Phase III Fianlimab-Libtayo trial.\n\nThe complaint cites significant stock drops of 6.2% and 9.8% in late April and mid-May 2026 following announcements regarding the trial's statistical significance.\n\nThis is a law-firm marketing communication soliciting investors to serve as lead plaintiff by September 14, 2026, not an issuer disclosure.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"customDimensions":{"case_number":"26-cv-6026","stock_drop_may_15":"9.8%","stock_drop_april_29":"6.2%","lead_plaintiff_deadline":"September 14, 2026"}},"quotedText":"","namedEntities":{"people":[{"name":"Adam McCall","role":"Contact at BFA Law"}],"products":["Fianlimab","Libtayo"],"companies":[{"name":"Regeneron Pharmaceuticals, Inc.","ticker":"REGN"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"},{"name":"Tesla, Inc.","relationship":"mentioned"},{"name":"Teva Pharmaceutical Ind. Ltd.","relationship":"mentioned"}],"dollarAmounts":[{"amount":"$45.41","context":"stock price decline on April 29, 2026"},{"amount":"$68.57","context":"stock price decline on May 15, 2026"},{"amount":"$900 million","context":"past recovery by BFA from Tesla Board"},{"amount":"$420 million","context":"past recovery by BFA from Teva"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Bleichmar Fonti & Auld LLP. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"REGN"},"globalImportance":15,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bleichmar Fonti & Auld LLP issued a shareholder-solicitation notice regarding a class action lawsuit against Regeneron, alleging securities fraud tied to the Phase III Fianlimab-Libtayo trial.\n\nThe complaint cites significant stock drops of 6.2% and 9.8% in late April and mid-May 2026 following announcements regarding the trial's statistical significance.\n\nThis is a law-firm marketing communication soliciting investors to serve as lead plaintiff by September 14, 2026, not an issuer disclosure.","key_figures":{"customDimensions":{"case_number":"26-cv-6026","stock_drop_may_15":"9.8%","stock_drop_april_29":"6.2%","lead_plaintiff_deadline":"September 14, 2026"}},"named_entities":{"people":[{"name":"Adam McCall","role":"Contact at BFA Law"}],"products":["Fianlimab","Libtayo"],"companies":[{"name":"Regeneron Pharmaceuticals, Inc.","ticker":"REGN"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"},{"name":"Tesla, Inc.","relationship":"mentioned"},{"name":"Teva Pharmaceutical Ind. Ltd.","relationship":"mentioned"}],"dollarAmounts":[{"amount":"$45.41","context":"stock price decline on April 29, 2026"},{"amount":"$68.57","context":"stock price decline on May 15, 2026"},{"amount":"$900 million","context":"past recovery by BFA from Tesla Board"},{"amount":"$420 million","context":"past recovery by BFA from Teva"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-03T10:50:51.487Z","global_importance":15,"audience_relevance":20,"importance_components":{"tickerTier":"large-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":189142,"modelName":"glm-4.7"}}